|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Change in fair value of warrant liability | |||||
| Change in fair value of convertible promissory notes | |||||
| Interest on convertible promissory notes payable | |||||
| Change in fair value of financial instruments | |||||
| Interest expense | |||||
| Interest income | |||||
| Other income | |||||
| Total other income (expense) | |||||
| Net loss | |||||
| Deemed distribution to convertible promissory note holders | |||||
| Net loss attributable to common stockholders | |||||
| Net loss per share - basic | |||||
| Net loss per share - diluted | |||||
| Weighted-average number of shares outstanding used in computing net loss per share - basic | |||||
| Weighted-average number of shares outstanding used in computing net loss per share - diluted | |||||
Loading...